Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Sodium oxybate→

Sodium oxybate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
502-85-2
PubChem CID
23663870
Molecular formula
C4H7NaO3
Molecular weight
126.09 g/mol
Drug class
Gamma-hydroxybutyrate (GHB/oxybate)central nervous system depressant
Mechanism of action
Acts through GHB and GABA-B receptor pathways. The precise mechanism by which sodium oxybate improves symptoms of narcolepsy is not fully understood; it affects sleep architecture and may consolidate nocturnal sleep, with downstream effects on cataplexy and excessive daytime sleepiness.
Indications / reported uses
  • Treatment of cataplexy in narcolepsy
  • Treatment of excessive daytime sleepiness in narcolepsy, including in paediatric patients where the formulation and local authorisation permit

Sources: US DailyMed — Sodium oxybate · FDA — Sodium oxybate product information

Identification source: PubChem record (CID 23663870). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Sodium oxybate Environmental Risk Assessment (ERA) (the Sodium oxybate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.